SUBSCRIBE
SUBSCRIBE
News   Business

Medivir AB to Receive Two Milestone Payments Amounting to 17 Million Euros in the Tibotec HCV Collaboration

December 14, 2007 | 
1 min read

STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Medivir (STO:MVIRB) is collaborating with Tibotec Pharmaceuticals Ltd to develop HCV NS3/4A Protease Inhibitors for the treatment of chronic hepatitis C virus (HCV) infection.

Alliances Europe
MORE ON THIS TOPIC
cutting off a row of people into pieces
Layoffs
Editas Axes 60% of Staff, Sickle Cell Therapy After Failing to Find Partner
December 13, 2024
 · 
2 min read
 · 
Tristan Manalac
Novo Nordisk advertising flags and logo on facade
Regulatory
Novo Nordisk Snags Kidney Disease Expansion for Ozempic in Europe
December 12, 2024
 · 
1 min read
 · 
Kate Goodwin
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
Bavarian, BenevolentAI, Chroma Medicine and Nvelop Therapeutics Cut Staff
December 12, 2024
 · 
205 min read
 · 
BioSpace Editorial Staff
Sign outside BioNTech's building in Germany
Breast cancer
BioNTech Builds Case for PD-L1/VEGF Bispecific With Promising Breast Cancer Data
December 11, 2024
 · 
2 min read
 · 
Tristan Manalac